The shares of Aurobindo Pharma gained nearly 8 per cent on Monday, reaching a new 52-week high after the company received approval under the Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical bulk drugs.
At 12:51 pm, Aurobindo Pharma was trading at ₹1005.45 on the BSE, up ₹81.80 or 8.86 per cent. It hit a 52-week high of ₹1,011.90. It opened at ₹930 as against the previous close of ₹923.65.
On the NSE, it was trading at 1,005.10, up ₹81.30 or 8.80 per cent. It hit a 52-week high of ₹1,012.00.
ALSO READFirst set of five bulk drug, pharma input projects under PLI scheme cleared
The government last week approved the first set of five pharma projects under the Production Linked Incentive (PLI) scheme for promoting domestic manufacture of bulk drugs and active pharmaceutical ingredients (APIs). These projects are worth a total committed investment of ₹3,761 crore.
ALSO READ Aurobindo, COVAXX ink deal to develop, commercialise Covid-19 vaccine for India, UNICEF
Aurobindo Pharma, through its subsidiaries including LyfiusPharma Pvt Ltd and Qule Pharma Pvt Ltd, received approval for three projects. The company, through its subsidiaries will launch projects for producing 15,000 tonne per annum (TPA) of Penicillin G, 2,000 tpa of 7-ACA and 1,600 tpa of erythromycin thiocyanate.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.